Invitae (NYSE: NVTA), a leading medical genetics company, today announced it has entered into a definitive agreement to acquire Ciitizen, a patient-centric consumer health tech company. Backed by a16z, Section 32 and Verily, Ciitizen is working to build a global platform to help patients collect, organize, store and share their medical records digitally. The acquisition would enhance Invitae's platform by providing patients an easy-to-use, centralized hub for their genomic and clinical information, which together comprise a powerful dataset with the potential to drive research and improve healthcare decision making.
top of page
Search
Recent Posts
See AllBy: Steven Loeb Venture capital used to be a cottage industry, with very few investing in tomorrow's products and services. Oh, how times...
Matterworks, Inc., developers of the world's most powerful metabolomics platform, which accelerates the discovery, development, and...
Luna, the leading provider of in-home physical therapy, has teamed up with UCI Health, to expand access to patient care by providing...
bottom of page
Commentaires